Interferon alpha-2A (roferon) as a treatment of inflammatory bowel disease in children and adolescents.
Hadziselimovic
F
F
Department of Gastroenterology, University Children's Hospital, Basel, Switzerland.
Schaub
U
U
Emmons
L R
LR
D000293:Adolescent; D002452:Cell Count; D002648:Child; D003093:Colitis, Ulcerative / Q000276:immunology / Q000473:pathology / Q000628:therapy; D003424:Crohn Disease / Q000276:immunology / Q000473:pathology / Q000628:therapy; D006801:Humans; D018928:Immunity, Mucosal / Q000187:drug effects; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D007694:Killer Cells, Natural / Q000276:immunology / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology / Q000473:pathology; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins